AR086576A1 - Composiciones de cb-183,315 y metodos relacionados - Google Patents

Composiciones de cb-183,315 y metodos relacionados

Info

Publication number
AR086576A1
AR086576A1 ARP120101868A ARP120101868A AR086576A1 AR 086576 A1 AR086576 A1 AR 086576A1 AR P120101868 A ARP120101868 A AR P120101868A AR P120101868 A ARP120101868 A AR P120101868A AR 086576 A1 AR086576 A1 AR 086576A1
Authority
AR
Argentina
Prior art keywords
compositions
related methods
solid
aqueous solution
trehalose
Prior art date
Application number
ARP120101868A
Other languages
English (en)
Inventor
Sandra Oconnor
Sophie Sun
Gaauri Naik
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of AR086576A1 publication Critical patent/AR086576A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La estabilidad química del CB-183.315 sólido depende del proceso por el cual se hace la composición. Los preparados sólidos de CB-183.315 se pueden hacer por el siguiente método: (a) formar una solución acuosa de CB-183.315 y por lo menos un azúcar (por ejemplo, sacarosa, trehalosa o dextrano) a un pH de 2 - 7, preferiblemente a pH 6 y (b) convertir la solución acuosa en el preparado sólido de CB-183.315 (por ejemplo, por liofilización o secado por aspersión).
ARP120101868A 2011-05-26 2012-05-28 Composiciones de cb-183,315 y metodos relacionados AR086576A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490584P 2011-05-26 2011-05-26

Publications (1)

Publication Number Publication Date
AR086576A1 true AR086576A1 (es) 2014-01-08

Family

ID=46208839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101868A AR086576A1 (es) 2011-05-26 2012-05-28 Composiciones de cb-183,315 y metodos relacionados

Country Status (12)

Country Link
US (2) US20130109633A1 (es)
EP (1) EP2714012A1 (es)
JP (1) JP2014515371A (es)
KR (1) KR20140037877A (es)
CN (1) CN103687589A (es)
AR (1) AR086576A1 (es)
BR (1) BR112013030369A2 (es)
CA (1) CA2837174A1 (es)
MX (1) MX2013013760A (es)
RU (1) RU2013157188A (es)
TW (1) TW201300124A (es)
WO (1) WO2012162567A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
CN109476704B (zh) * 2016-04-08 2022-08-16 港大科桥有限公司 抗菌环脂肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044271A2 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
EP2263654B1 (en) * 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Compositions for improving the oral absorption of antimicrobial agents
US20030045678A1 (en) * 2000-12-18 2003-03-06 Dennis Keith Methods for preparing purified lipopeptides
EP1814588A2 (en) * 2004-11-12 2007-08-08 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RS53152B (en) 2008-12-22 2014-06-30 Cubist Pharmaceuticals Inc. NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF Gram POSITIVE INFECTIONS
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
CN102060914B (zh) * 2009-11-13 2014-09-17 华东理工大学 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用
EP2504020A4 (en) * 2009-11-23 2013-05-29 Eagle Pharmaceuticals Inc DAPTOMYCIN FORMULATIONS
MX2012005993A (es) * 2009-11-23 2012-11-23 Cubist Pharm Inc Composiciones de lipopeptido y metodos relacionados.

Also Published As

Publication number Publication date
EP2714012A1 (en) 2014-04-09
CA2837174A1 (en) 2012-11-29
BR112013030369A2 (pt) 2016-12-13
MX2013013760A (es) 2014-01-08
JP2014515371A (ja) 2014-06-30
CN103687589A (zh) 2014-03-26
US20130109633A1 (en) 2013-05-02
WO2012162567A1 (en) 2012-11-29
US20140135273A1 (en) 2014-05-15
KR20140037877A (ko) 2014-03-27
RU2013157188A (ru) 2015-07-10
TW201300124A (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
BR112015013822A2 (pt) método de vaso único para a síntese de cu-ssz-13, o composto obtido através do método e utilização do mesmo
WO2017070616A3 (en) Sexually transmitted disease vaccines
WO2017070626A3 (en) Respiratory virus vaccines
PE20181400A1 (es) Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
EA202090675A3 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
BR112015015031A2 (pt) processo de glicoconjugação
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
BR112015030326A2 (pt) Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
UA115357C2 (uk) Похідні піридин-4-ілу
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
BR112018014401A2 (pt) composições pulverizadas sólidas com substâncias ativas de superfície em carreadores solúveis em água sólidos, seu processo para a produção e uso das mesmas?
UY35848A (es) Tienopirimidinas
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA201992832A1 (ru) Подкожное введение adamts13
WO2016038521A8 (en) Pharmaceutical compositions of liraglutide
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201990163A1 (ru) Консервация микроорганизмов
WO2013117771A3 (en) Cosmetic treatment method, and composition comprising a glyoxylic acid derivative

Legal Events

Date Code Title Description
FB Suspension of granting procedure